Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

NCT00628108 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Rhinitis
Chronic Urticaria

Interventions

DRUG: Levocetirizine 1.25 mg
OTHER: Placebo

Sponsor

UCB Pharma